Reply to: ‘Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan’

Abstract

We would like to thank Dr. Nakatsuka and colleagues [1] for their interest in our previously proposed [2] algorithms for de-novo hepatocellular carcinoma (HCC) risk stratification in compensated advanced chronic liver disease (cACLD) patients who achieved sustained virologic response (SVR). In their letter to the editor [1], they set out to validate our algorithms in a Japanese cohort including a subgroup of 183 cACLD patients.